Cortigent, INC S-1 registration statements

Cortigent, Inc. has filed an S-1/A amendment with the SEC, detailing its initial public offering to raise capital for its advanced neurostimulation technologies aimed at restoring vision and aiding stroke recovery.

Cortigent, a pre-revenue neurostimulation company, is pursuing a $15 million IPO to advance its artificial vision and stroke recovery systems, despite ongoing operating losses and a 'going concern' warning.

Cortigent, a pre-revenue neurostimulation company, files for an initial public offering to fund the development of its Orion artificial vision and Stroke Recovery Systems, despite ongoing operating losses and going concern doubts.

Cortigent, a pioneer in neurostimulation, is launching an IPO to fund the development of its Orion artificial vision system and Stroke Recovery System, targeting significant unmet medical needs despite a history of operating losses.

Cortigent, a neurostimulation technology company, is seeking to raise approximately $15 million through an initial public offering to fund the development of its Orion visual prosthesis and stroke recovery system.

Cortigent, a neurostimulation technology company, is seeking to raise $15 million through an initial public offering to fund the development of its Orion visual prosthesis and stroke recovery system.

Cortigent, a neurostimulation technology company, is seeking to raise $15 million through an initial public offering to fund the development of its Orion visual prosthesis and stroke recovery system.

Cortigent, a neurostimulation technology company, aims to raise approximately $15 million through an initial public offering to fund the development of its Orion visual prosthesis and stroke recovery system.

Cortigent, a neurostimulation technology company, aims to raise $15 million through an IPO to fund clinical trials for its Orion artificial vision system and stroke recovery technology.

Cortigent, a neurostimulation technology company, aims to raise $15 million through an IPO to fund clinical trials and development of its Orion visual prosthesis and stroke recovery system.

Cortigent, a neurostimulation technology company, is seeking to raise approximately $15 million through an initial public offering to fund the development of its Orion visual prosthesis and stroke recovery system.

Cortigent, a neurostimulation technology company, is seeking to raise approximately $15 million through an initial public offering to fund the development of its Orion artificial vision system and stroke recovery technology.